18 and older, any sex, with Hematopoietic/Lymphoid Cancer or Richter's Transformation. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants With a ResponsePrimary· 2 months
Response is defined as complete remission (CR) plus partial remission (PR). Complete Remission (CR) is Lymph nodes None \>/= 1.5 cm, Spleen size \< 13 cm; normal liver size, the absence of constitutional symptoms, normal circulating lymphocyte count, platelets \>/= 100 x 10\^9/L, Hemoglobin \>/= 11.0 g/dL (absence of transfusion and without erythropoietin) and marrow normocellular, no CLL cells and no B-lymphoid nodules. Partial Remission (PR) is any two of the following must decrease \>/= 50% from baseline: lymph nodes, Liver and/or spleen size, circulating lymphocyte count in addition to one
Group
Value
95% CI
Ibrutinib, Nivolumab and Blinatumomab
2
Number of Participants to Achieve Complete RemissionSecondary· Up to 4 years, 8 months
Complete Remission is defined as: Complete Remission (CR) is Lymph nodes None \>/= 1.5 cm, Spleen size \< 13 cm; normal liver size, the absence of constitutional symptoms, normal circulating lymphocyte count, platelets \>/= 100 x 10\^9/L, Hemoglobin \>/= 11.0 g/dL (absence of transfusion and without erythropoietin) and marrow normocellular, no CLL cells and no B-lymphoid nodules.
Group
Value
95% CI
Ibrutinib, Nivolumab and Blinatumomab
1
Progression Free SurvivalSecondary· Up to 4 years, 8 months
Time from date of treatment start until the date of first objective documentation of disease-relapse.
Group
Value
95% CI
Ibrutinib, Nivolumab and Blinatumomab
1.9
1 – 17
Overall SurvivalSecondary· Up to 4 years, 8 Months
Time from date of treatment start until date of death due to any cause or last Follow-up.
Group
Value
95% CI
Ibrutinib, Nivolumab and Blinatumomab
10.3
5 – 48
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to 4 years, 8 months.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Ibrutinib, Nivolumab and Blinatumomab
Serious: 9/9 (100%)
Deaths: 0/9
Serious adverse events (12 terms)
Reaction
System
Ibrutinib, Nivolumab and B…
Lung Infection
Infections and infestations
—
Hypercalcemia
Metabolism and nutrition disorders
—
Cytokine Release Syndrome
Immune system disorders
—
Fracture
Injury, poisoning and procedural complications
—
Nervous System Disorder
Nervous system disorders
—
Creatinine Increased
Investigations
—
Chills
General disorders
—
Fatigue
General disorders
—
Hypotension
Vascular disorders
—
Metabolism and nutrition disorders - Other, specify
Metabolism and nutrition disorders
—
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
—
Fever
General disorders
—
Other adverse events (55 terms — click to expand)
Reaction
System
Ibrutinib, Nivolumab and B…
Fever
General disorders
—
Fatigue
General disorders
—
Alkaline phosphatase increased
Investigations
—
Hypercalcemia
Metabolism and nutrition disorders
—
Investigations
Investigations
—
Lung infection
Infections and infestations
—
Tremor
Nervous system disorders
—
Alanine aminotransferase increased
Investigations
—
Confusion
Psychiatric disorders
—
Creatinine increased
Investigations
—
Cytokine release syndrome
Immune system disorders
—
Edema
General disorders
—
General disorders and administration site conditions
The goal of this clinical research study is to learn if blinatumomab can help to control Richter Transformation (RT, a type of blood cancer). The safety of this drug will also be studied.
This is an investigational study. Blinatumomab is FDA approved and commercially available for the treatment of acute lymphoblastic leukemia (ALL). It is investigational to use blinatumomab to treat patients with RT. The study doctor can explain how the study drug is designed to work.
Up to 21 participants will be enrolled in this study. All will take part at MD Anderson.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07192237 — Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Diseas
· Phase 2
· not yet recruiting
NCT07178912 — Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromoso
· Phase 2
· not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+
· Phase 1, PHASE2
· not yet recruiting
NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage
· NA
· not yet recruiting
NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly
· Phase 3
· not yet recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem
· Phase 1, PHASE2
· not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and
· Phase 1
· not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che
· Phase 2
· not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca
· Phase 2
· not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar
· Phase 1
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 17 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03121534.